CN108601952B - 雷公藤内酯的葡萄糖缀合物、类似物及其用途 - Google Patents

雷公藤内酯的葡萄糖缀合物、类似物及其用途 Download PDF

Info

Publication number
CN108601952B
CN108601952B CN201780010159.3A CN201780010159A CN108601952B CN 108601952 B CN108601952 B CN 108601952B CN 201780010159 A CN201780010159 A CN 201780010159A CN 108601952 B CN108601952 B CN 108601952B
Authority
CN
China
Prior art keywords
cancer
syndrome
disease
autoimmune
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780010159.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108601952A (zh
Inventor
J·刘
何庆丽
M·G·庞珀
闵逸
于彪
王巧玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN108601952A publication Critical patent/CN108601952A/zh
Application granted granted Critical
Publication of CN108601952B publication Critical patent/CN108601952B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
CN201780010159.3A 2016-02-04 2017-02-03 雷公藤内酯的葡萄糖缀合物、类似物及其用途 Active CN108601952B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291416P 2016-02-04 2016-02-04
US62/291,416 2016-02-04
PCT/US2017/016527 WO2017136739A1 (en) 2016-02-04 2017-02-03 Glucose conjugates of triptolide, analogs and uses thereof

Publications (2)

Publication Number Publication Date
CN108601952A CN108601952A (zh) 2018-09-28
CN108601952B true CN108601952B (zh) 2022-03-04

Family

ID=59500284

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780010159.3A Active CN108601952B (zh) 2016-02-04 2017-02-03 雷公藤内酯的葡萄糖缀合物、类似物及其用途

Country Status (8)

Country Link
US (2) US10695319B2 (cg-RX-API-DMAC10.html)
EP (1) EP3411121B1 (cg-RX-API-DMAC10.html)
JP (1) JP7042744B2 (cg-RX-API-DMAC10.html)
CN (1) CN108601952B (cg-RX-API-DMAC10.html)
AU (1) AU2017214572A1 (cg-RX-API-DMAC10.html)
CA (1) CA3013619A1 (cg-RX-API-DMAC10.html)
MX (1) MX2018009406A (cg-RX-API-DMAC10.html)
WO (1) WO2017136739A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942665B (zh) * 2018-04-02 2021-04-06 欣凯医药化工中间体(上海)有限公司 雷公藤内酯醇衍生物及其制备方法和应用
CN111500467B (zh) * 2019-03-28 2021-11-02 中国医学科学院医药生物技术研究所 一种制备抗丙型肝炎病毒活性化合物雷斯吲哚甲的海洋青霉菌
JP7353500B2 (ja) 2019-12-30 2023-09-29 グゥアンドン プロビンシャル ホスピタル オブ ティーシーエム アクリル酸トリプトリド、その調製方法および用途
CN111040018A (zh) * 2019-12-30 2020-04-21 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) 丙烯酸雷公藤甲素酯、其制备方法及其应用
CN115715201A (zh) * 2020-03-02 2023-02-24 约翰霍普金斯大学 葡萄糖雷公藤甲素缀合物及其用途
EP4200022A1 (en) * 2020-08-21 2023-06-28 Reyoung Corporation Triptolide conjugates and uses thereof
CN115286684A (zh) * 2022-05-20 2022-11-04 福建医科大学 一种糖与雷公藤内酯醇或其衍生物的缀合物及其制备方法与应用
WO2024186319A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer
AU2025207356A1 (en) 2024-01-11 2026-08-06 Minneamrita Therapeutics Llc Triptolide formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099051A1 (en) * 2001-01-19 2002-07-25 Fidler John M. Anticancer treatment using triptolide prodrugs
US6569893B2 (en) * 2001-03-15 2003-05-27 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
US20140107077A1 (en) * 2009-05-07 2014-04-17 Regents Of The University Of Minnesota Triptolide prodrugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218367B1 (en) * 1998-09-15 2001-04-17 Organomed Corporation Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099051A1 (en) * 2001-01-19 2002-07-25 Fidler John M. Anticancer treatment using triptolide prodrugs
US6569893B2 (en) * 2001-03-15 2003-05-27 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
US20140107077A1 (en) * 2009-05-07 2014-04-17 Regents Of The University Of Minnesota Triptolide prodrugs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
(14S)-14-O-beta-D-Glucopyranosyltriptolide;——;《DATABASE PUBCHEM》;20151218;1 *
——.(14S)-14-O-beta-D-Glucopyranosyltriptolide.《DATABASE PUBCHEM》.2015,1. *
Chemo-enzymatic Synthesis of Propionyl-ester-linked Taxol-monosaccharide Conjugate and its Drug Delivery System Using Hybrid-Bio-nanocapsules Targeting Brain Glioma Cells;Hiroki Hamada et al.;《Clinical Medicine Insights:Women’s Health》;20131231;第6卷;71-75 *
Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties;Pengxing Liu et al.;《CHEMICAL COMMUNICATIONS》;20130201;第49卷;2421-2423 *
Synthesis of 2’-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cells;Der-Zen Liu et al.;《Bioorganic & Medicinal Chemistry Letters》;20061107;第17卷;617-620 *

Also Published As

Publication number Publication date
JP2019509986A (ja) 2019-04-11
MX2018009406A (es) 2018-11-09
AU2017214572A1 (en) 2018-08-16
US20200297693A1 (en) 2020-09-24
US10695319B2 (en) 2020-06-30
CN108601952A (zh) 2018-09-28
WO2017136739A1 (en) 2017-08-10
US20190038596A1 (en) 2019-02-07
EP3411121A1 (en) 2018-12-12
CA3013619A1 (en) 2017-08-10
EP3411121B1 (en) 2024-09-11
EP3411121A4 (en) 2019-12-18
JP7042744B2 (ja) 2022-03-28

Similar Documents

Publication Publication Date Title
EP3411121B1 (en) Glucose conjugates of triptolide, analogs and uses thereof
KR102679892B1 (ko) 화합물 및 이의 접합체
KR102396307B1 (ko) 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
ES2918425T3 (es) Conjugados de anticuerpo-fármaco
HRP20201446T1 (hr) Konjugati analoga cc-1065 i bifunkcionalnih veznika
JP7103953B2 (ja) 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート
ES2576497T3 (es) Compuesto de piperidina novedoso o sal del mismo
JP2019529444A5 (cg-RX-API-DMAC10.html)
JP2016505586A5 (cg-RX-API-DMAC10.html)
JP2016506916A5 (cg-RX-API-DMAC10.html)
AU2016279051B2 (en) Delivery systems for controlled drug release
JP2019504100A5 (cg-RX-API-DMAC10.html)
JP2018507844A (ja) 抗体薬物コンジュゲート
EP3458069A2 (en) Pyrrolobenzodiazepines and conjugates thereof
ES2702911T3 (es) Agente antitumoral que incluye una baja dosis de clorhidrato de irinotecán hidratado
JP2009530424A5 (cg-RX-API-DMAC10.html)
JP2012528240A5 (cg-RX-API-DMAC10.html)
JP2015527318A5 (cg-RX-API-DMAC10.html)
JP2019509986A5 (cg-RX-API-DMAC10.html)
JP2014524449A5 (cg-RX-API-DMAC10.html)
ES2685974T3 (es) Derivados de cefalosporina para tratar el cáncer
TW202434231A (zh) 包含依喜替康衍生物之靶向uPARAP的抗體-藥物結合物
JP6580030B2 (ja) カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途
JP2023514520A (ja) ベンゾセレノフェン系化合物、これを含む薬学的組成物及び抗体-薬物複合体
ES2824400T3 (es) Agente antitumoral que incluye clorhidrato de irinotecán hidratado

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: J.Liu

Inventor after: He Qingli

Inventor after: M.G. Pomper

Inventor after: Min Yi

Inventor after: Yu Biao

Inventor after: Wang Qiaoling

Inventor before: J.Liu

Inventor before: He Qingli

Inventor before: M.G. Pomper

Inventor before: Ai Miln

Inventor before: Yu Biao

Inventor before: Wang Qiaoling

GR01 Patent grant
GR01 Patent grant